Omeros' Q4 2025: A Turning Point for the Biotech Company
Omeros, a biopharmaceutical company, marked a significant milestone in its fourth quarter of 2025 with two major successes that have set the stage for future growth and expansion. On November 25, Omeros closed an asset purchase and license transaction with Novo Nordisk for its phase III-ready asset zaltenibart, while on December 23, the company received FDA approval for narsoplimab, now commercialized under the brand name YARTEMLEA.
The deal with Novo Nordisk was a major coup for Omeros, valuing up to $2.1 billion in upfront and milestone payments. The transaction granted Novo Nordisk exclusive global rights to develop and commercialize zaltenibart, while Omeros retained the rights to its MASP-3 small molecule program. As part of the deal, Omeros received an upfront cash payment of $240 million, with additional milestones totaling up to $1.5 billion.
"This transaction is a testament to the value and potential of our science and development expertise," said Dr. Greg Demopulos, Chairman and CEO of Omeros. "We are proud to partner with Novo Nordisk to unlock the full potential of zaltenibart and bring new hope to patients suffering from these diseases."
The FDA approval for YARTEMLEA marked another significant achievement for Omeros, making it the first and only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). MASP-2 is the effector enzyme of the lectin pathway of complement, and TA-TMA is driven by lectin pathway activation. The FDA-approved indication for YARTEMLEA covers all TA-TMA in both adults and children at least two years of age.
"We are thrilled to bring YARTEMLEA to market as a safe and effective treatment option for patients with TA-TMA," added Dr. Demopulos. "This approval is a testament to the hard work and dedication of our team, and we look forward to making a meaningful difference in the lives of these patients."
The success of Omeros' Q4 2025 results has sent shockwaves through the biotech industry, solidifying the company's position as a leader in the development of novel therapeutics. As Omeros continues to push the boundaries of science and innovation, one thing is certain: these landmark achievements have set the stage for a bright future.
